Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system

Cancer

Volumn 112, Issue 3, 2008, Pages 581-588

  Jahnke, Kristoph ^a   Kraemer, Dale F ^b,c   Knight, Kristin R ^b   Fortin, David ^d   Bell, Susan ^e   Doolittle, Nancy D ^a   Muldoon, Leslie L ^a,b   Neuwelt, Edward A ^a,b,f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier disruption; Embryonal tumors; Germ cell tumors

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; MANNITOL; METHOTREXATE; PROCARBAZINE; SODIUM THIOSULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTERY INJURY; ARTERY THROMBOSIS; ARTICLE; AVASCULAR NECROSIS; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DISRUPTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; CERVICAL SPINAL CORD INJURY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEMENTIA; DRUG DELIVERY SYSTEM; EMBRYONAL CARCINOMA; EPILEPTIC STATE; ERYTHROCYTE TRANSFUSION; EYE DISEASE; FEBRILE NEUTROPENIA; FEMALE; FEMORAL ARTERY INJURY; FEMORAL ARTERY THROMBOSIS; FRACTURE; GERM CELL TUMOR; HEARING LOSS; HEART ARRHYTHMIA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PINEAL BODY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SEPTICEMIA; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE TRANSFUSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; CARBOPLATIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; INFANT; INFUSIONS, INTRA-ARTERIAL; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38749147731     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23221     Document Type: Article

References (34)

1. Kleihues P, Cavenee WK (eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC; 2000.
2. Sarkar C, Deb P, Sharma MC. Recent advances in embryonal tumours of the central nervous system. Childs Nerv Syst. 2005;21:272-293.
3. Rorke LB, Hart MN, McLendon RE. Supratentorial primitive neuroectodermal tumour. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC; 2000:141-144.
4. Packer RJ. Progress and challenges in childhood brain tumors. J. Neurooncol. 2005;75:239-242.
5. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-4208.
6. Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A, Sainte-Rose C, Pierre-Kahn A, Hirsch JF. Medulloblastoma in childhood: progressive intellectual deterioration. Childs Nerv Syst. 1990;6:60-65.
7. Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol. 1999;17:3720-3728.
8. Ilveskoski I, Saarinen UM, Wiklund T, et al. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Med Pediatr Oncol. 1998;27:26-31.
9. Ironside JW, Moss TH, Louis DN, Lowe JS, Weiler RO. Embryonal tumours. In: Ironside JW, Moss TH, Louis DN, Lowe JS, Weiler RO, eds. Diagnostic Pathology of Nervous System Tumours. London: Churchill Livingstone; 2002:185-215.
10. Bamberg M, Kortmann RD, Calaminus G, et al. Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol. 1999;17:2585-2592.
11. Calaminus G, Andreussi L, Garre ML, Kortmann RD, Schober R, Gobel U. Secreting germ cell tumors of the central nervous system (CNS). First results of the cooperative German/Italian pilot study (CNS sGCT). Klin Padiatr. 1997;209:222-227.
12. Allen JC, Kim JH, Packer RJ. Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. J Neurosurg. 1987;67:65-70.
13. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery. 2004;54:131-140.
14. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46:51-60.
15. Doolittle ND, Murillo TP, Neuwelt EA. Blood-brain barrier disruption chemotherapy. In: Newton HB, ed. Handbook of Brain Tumor Chemotherapy. London: Elsevier; 2006:262-273.
16. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
17. Neuwelt EA, Brummett RE, Doolittle ND, et al. First evidence of otoprotection against carboplatin-induced hearing loss with a 2-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther. 1998;286:77-84.
18. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493-500.
19. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery. 2001;48:1033-1040.
20. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637-647.
21. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17:832-845.
22. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer. 2000;88:2189-2193.
23. Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol. 1995;13:1687-1696.
24. Timmermann B, Kortmann RD, Kuhl J, et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol. 2002;20:842-849.
25. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81:690-698.
26. Dahlborg SA, Petrillo A, Crossen JR, et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am. 1998;4:110-124.
27. Strother D, Ashley D, Kellie SJ, et al. Feasibility of 4 consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001;19:2696-2704.
28. Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004;22:4881-4887. [Erratum: J Clin Oncol. 23:2877, 2005.]
29. Sung KW, Yoo KH, Cho EJ, et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer. 2007;48:408-415.
30. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, Sevilla J, Diaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol. 2005;71:33-38.
31. Grill J, Sainte-Rose C, Jouvet A, et al. French Society of Paediatric Oncology. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6:573-580.
32. Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation - a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial-the First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol. 1996;14:2908-2915.
33. Kellie SJ, Boyce H, Dunkel IJ, et al. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol. J Clin Oncol. 2004;22:846-853.
34. Modak S, Gardner S, Dunkel IJ, et al. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol. 2004;22:1934-1943.